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Caffeine, theophylline, and ciprofloxacin

Abstract
Dynamics of interactions between the drugs caffeine,
theophylline, and ciprofloxacin are predicted using
physiologically-based pharmacokinetic (PBPK)
modeling. Pharmacokinetic means the model
determines where the drugs are distributed in the body
over time. Physiologically-based means the anatomy
and physiology of the human body are reflected in the
structure and functioning of the model. Multiple drugs
can interact to increase or decrease their beneficial
and/or undesired effects. This is important because
some common substances, such as caffeine in coffee,
soft drinks, and energy drinks, are actually drugs that
affect the body. Ciprofloxacin is an inhibitor of caffeine
and theophylline metabolism; such inhibition can lead
to an overdose of caffeine and theophylline, and a
reduced therapeutic effect for ciprofloxacin. PBPK
modeling can be used by medical professionals to more
precisely prescribe drug doses to achieve the desired
therapeutic effects while minimizing the unwanted side
effects by accounting for all drugs taken concurrently
as well as lifestyle choices such as consumption of
caffeinated beverages.

Physiologically-based
8
pharmacokinetic (PBPK) modeling

• Caffeine (top left) is a common psychoactive
stimulant found in coffee, tea, soft drinks, and
energy drinks.
• Theophylline (middle left) is used to treat
respiratory conditions such as asthma, infant
apnea, and chronic obstructive pulmonary
disease (COPD).
• Ciprofloxacin (lower left) is an antimicrobial used
to treat bacterial infections by inhibiting DNA
and protein synthesis.7 It is also used by the
military to protect against anthrax, a biological
weapon. Ciprofloxacin slows the rate at which the
body eliminates caffeine and theophylline.6

Metabolism, drug interactions, and toxicity
Metabolism: The diagram (right) shows pathways
(arrows) by which caffeine, for example, is broken
down in the liver by enzymes:
• Caffeine is broken down into theophylline by the
enzyme CYP1A2.
• Theophylline is also broken down by CYP1A2.

Drug Interactions
• A drug may affect the activity of another by altering its metabolism.
• Ciprofloxacin inhibits CYP1A2 by binding to it.4
• This slows down the metabolism of caffeine and theophylline which
effectively increases their dose.
• The dose of ciprofloxacin is also effectively decreased.
• KI is the dissociation constant of the enzyme-inhibitor complex.

Results
• A PBPK model for caffeine, theophylline, and ciprofloxacin was implemented using the Mathematica program.5, 9
• Figures 1 and 2 show good correspondence between the model’s predictions (curves) with experimental data (points)
for theophylline14 and ciprofloxacin1, 2, 3.
• Many common beverages contain caffeine at relatively high doses.17 Figure 3 shows predicted plasma caffeine
concentrations six hours after consuming a single serving of various beverages.

Figure 1: Concentration of theophylline in the venous system: model
prediction (curve) and experimental data (points) for the same
theophylline dose have the same color.

Figure 2: Concentration of ciprofloxacin in the venous system: model
prediction (curve) and experimental data (points) for the same
ciprofloxacin dose have the same color.

• Ciprofloxacin inhibits CYP1A2. Mahr et al. provide experimental results for caffeine plasma levels when
coadministered with ciprofloxacin.10 Fuhr et al. provide a value for KI : 0.18 mM.4 The model predicts a
poor match with experiment given this value for KI , and predicts a value of 1.4 μM for KI (data not shown).
• Figure 4 shows the serum concentration of theophylline when administered alone (blue), and that
theophylline administered with ciprofloxacin (red) leads to theophylline intoxication12 (exceeds black line)
due to ciprofloxacin’s inhibition of CYP1A2, even when the doses of both drugs are consistent with
therapeutic guidelines13.

Toxicity

Example PBPK model9

Example human
(Charles Darwin)

The block diagram (left) is an example of how a human
(right) can be modeled:
• Organs appear as compartments (blocks) connected
by blood flow (arrows).
• The model is described using differential equations.
Pharmacokinetics is divided into several processes:
• Absorption: Drugs can enter the body through
various portals such as intravenous or oral routes.
• Distribution: Drugs circulate through the body via
blood flow, or accumulate in tissue.
• Metabolism: Drugs may be changed or broken down
into other substances by enzymes.
• Elimination: Drugs or their metabolic products are
eliminated from the body through various routes
including the kidney (urine), liver, or lungs.

• Theophylline intoxication occurs at a plasma level of 20 mg/L; toxicity
occurs at 60 mg/L for chronic overdoses and at 100 mg/L for an acute
overdose, and can result in seizures, arrhythmias, and death.12, 16
• For caffeine, 400 mg/day is a safe dose for healthy adults11, 200
mg/day for pregnant women15, and 2.5 mg/day per kg body mass for
children 11 (e.g., 80 mg/day for an average 10 year old 17).
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Figure 3: Predicted plasma concentrations of caffeine six hours after
ingesting a single serving of various beverages (as a percentage of the
recommended daily limit for healthy adults). Black bars denote
recommended daily limits; blue bars denote beverages.

Figure 4: Concentration of theophylline in the venous system. The
black line (20 mg/L) indicates the level for theophylline intoxication.
The blue curve shows that theophylline given alone has a maximum
concentration near the intoxication level, but given in combination
with ciprofloxacin will exceed the intoxication level (both drugs given
within dosage guidelines).

Conclusion and future work
• Theophylline and ciprofloxacin, both prescribed within therapeutic guidelines, can, in combination, lead to
theophylline intoxication due to ciprofloxacin’s inhibitory effect on theophylline metabolism.
• The model predicts a value for KI for ciprofloxacin-CYP1A2 significantly different from the in vitro value
determined by Fuhr et al.
• Model development will continue with the inclusion of ciprofloxacin metabolism, leading to publication.
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